Dr. Michael C. Burnette, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 319
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME0747924 -
Rheumatology Physician
FL license ME0747924
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
- Morton Plant Hospital Clearwater, FL
- South Florida Baptist Hospital Plant City, FL
Medical groups
- Baycare Medical Group, Inc. (1,547 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 319
- Services billed
- 2,437
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 776 | 265 |
| Established patient office or other outpatient visit, 20-29 minutes | 177 | 116 |
| Aspiration and/or injection of fluid from large joint | 56 | 31 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 54 | 13 |
| Injection, methylprednisolone acetate, 40 mg | 53 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 39 | 39 |
| Injection of drug or substance under skin or into muscle | 22 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Valrico, FL | 704 |
| Hydroxychloroquine Sulfate Other prescribers in Valrico, FL | 516 |
| Methotrexate (methotrexate sodium) Other prescribers in Valrico, FL | 440 |
| Tramadol Hcl Other prescribers in Valrico, FL | 376 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Valrico, FL | 376 |
| Gabapentin Other prescribers in Valrico, FL | 253 |
| Leflunomide Other prescribers in Valrico, FL | 246 |
| Meloxicam Other prescribers in Valrico, FL | 234 |
| Pregabalin Other prescribers in Valrico, FL | 204 |
| Celecoxib Other prescribers in Valrico, FL | 158 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 106 payments worth $2,225 in total to this clinician.
| AbbVie Inc. | $465 |
|---|---|
| UCB, Inc. | $321 |
| AstraZeneca Pharmaceuticals LP | $235 |
| Amgen Inc. | $196 |
| Pfizer Inc. | $187 |
| Janssen Biotech, Inc. | $183 |
| Novartis Pharmaceuticals Corporation | $143 |
| Mallinckrodt Hospital Products Inc. | $89.20 |
| Food and Beverage | $2,125 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 7, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 4 companies. The companies reported $353,513 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS)
Amgen Inc. - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
E.r. Squibb & Sons, L.l.c. - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. · Active, not recruiting · NCT02629159 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. - M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)
AbbVie Inc. - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.